Chongqing Zhifei Biological Products Co.Ltd(300122) april 27 announced that the company achieved an operating revenue of 8.841 billion yuan in the first quarter, with a year-on-year increase of 125.16%; The net profit attributable to the parent company was 1.923 billion yuan, a year-on-year increase of 104.95%. In view of the significant increase in operating revenue, the company said that it was mainly due to the continuous growth of sales in the current period.
According to the first quarterly report of the company, the cooperation between Chongqing Zhifei Biological Products Co.Ltd(300122) and MSD is in normal progress. In the first quarter of 2022, the number of batches issued by the company’s agent products increased significantly compared with the same period of the previous year, with the batch issuance of 2.11 million tetravalent HPV vaccines, an increase of nearly 70%; Nine valent HPV vaccines were issued in batches of 4.83 million, an increase of nearly 280%; 3.24 million pentavalent rotavirus vaccines were issued in batches, an increase of nearly 220%; 48 Shenzhen Universe (Group) Co.Ltd(000023) valent pneumonia vaccines were issued in batches, an increase of more than 100%.
